184 related articles for article (PubMed ID: 35579925)
21. Administration Technique and Acceptance of Inhaler Devices in Patients With Asthma or COPD.
Sadowski CA; Cor K; Cave A; Banh HL
Ann Pharmacother; 2015 Jun; 49(6):639-48. PubMed ID: 25814632
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
23. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment.
Tervonen T; Martinez FJ; Hanania NA; Heidenreich S; Eudicone JM; Gilbert I
Respir Med; 2021 Jan; 176():106278. PubMed ID: 33387985
[TBL] [Abstract][Full Text] [Related]
24. Considerations in establishing bioequivalence of inhaled compounds.
Mayers I; Bhutani M
Expert Opin Drug Deliv; 2018 Feb; 15(2):153-162. PubMed ID: 28918665
[TBL] [Abstract][Full Text] [Related]
25. Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021.
Feldman WB; Tu SS; Alhiary R; Kesselheim AS; Wouters OJ
JAMA; 2023 Jan; 329(1):87-89. PubMed ID: 36594955
[TBL] [Abstract][Full Text] [Related]
26. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
[TBL] [Abstract][Full Text] [Related]
27. Inhaler devices in asthma and COPD patients - a prospective cross-sectional study on inhaler preferences and error rates.
Schreiber J; Sonnenburg T; Luecke E
BMC Pulm Med; 2020 Aug; 20(1):222. PubMed ID: 32819337
[TBL] [Abstract][Full Text] [Related]
28. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
29. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
30. [The importance of selecting the right type of inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD)].
Larsson K; Bjermer L; Svartengren M
Lakartidningen; 2019 Feb; 116():. PubMed ID: 30720857
[TBL] [Abstract][Full Text] [Related]
31. Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
[TBL] [Abstract][Full Text] [Related]
32. Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications.
McCabe H; Godman B; Kurdi A; Johnston K; MacBride-Stewart S; Lennon J; Hurding S; Bennie M; Morton A
Expert Rev Respir Med; 2019 Jul; 13(7):679-689. PubMed ID: 31189394
[No Abstract] [Full Text] [Related]
33. Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients.
Luke MC; Kozak D
J Ocul Pharmacol Ther; 2021 Apr; 37(3):157-161. PubMed ID: 33332225
[TBL] [Abstract][Full Text] [Related]
34. Inhaler technique in asthma and COPD: challenges and unmet knowledge that can contribute to suboptimal use in real life.
Melani AS
Expert Rev Clin Pharmacol; 2021 Aug; 14(8):991-1003. PubMed ID: 33983092
[No Abstract] [Full Text] [Related]
35. Developments in inhaled combination therapies: patent activity 2013-2014.
Norman P
Expert Opin Ther Pat; 2015; 25(11):1239-45. PubMed ID: 26135360
[TBL] [Abstract][Full Text] [Related]
36. Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD.
Feldman WB; Bloomfield D; Beall RF; Kesselheim AS
Nat Biotechnol; 2022 Sep; 40(9):1319-1325. PubMed ID: 36085503
[TBL] [Abstract][Full Text] [Related]
37. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
[TBL] [Abstract][Full Text] [Related]
38. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W
Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177
[TBL] [Abstract][Full Text] [Related]
39. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
Rome BN; Lee CC; Kesselheim AS
Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
[TBL] [Abstract][Full Text] [Related]
40. Inhaler devices for patients with COPD.
Fink JB; Colice GL; Hodder R
COPD; 2013 Aug; 10(4):523-35. PubMed ID: 23537191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
